HealthTech and MedTech Mergers and Acquisitions Predictions for 2026

Nelson Advisors
7 minutes ago
16 min read

Executive Summary: The 2026 HealthTech and MedTech Deal Thesis

The Mergers and Acquisitions (M&A) landscape for HealthTech and MedTech is poised for a significant strategic acceleration in 2026, transitioning from cautious, volume-driven dealmaking witnessed in previous years to high-value, transformative transactions.

This resurgence is supported by stabilising credit markets, renewed corporate confidence, and a critical, anticipated pivot in US. antitrust enforcement policy, which is expected to facilitate large, strategic combinations. The single most potent catalyst driving deal value across both sectors is the urgent necessity to acquire advanced Artificial Intelligence (AI) and Generative AI (GenAI) capabilities, crucial for driving operational efficiency, streamlining workflows, and mitigating persistent margin compression.

The market dynamic is shifting from a focus purely on innovation to one demanding demonstrable return on investment (ROI) derived from technological integration. Private Equity (PE) involvement remains high, supported by robust dry powder reserves, with sponsors focusing on both platform expansion and realising delayed exits into a receptive corporate buyer market.

Strategic Forecast at a Glance

The year 2026 is projected to witness a substantial increase in the share of mega deals ($5 Billion and above), following the momentum established in 2025. The strategic imperative for incumbents is twofold: defensive acquisitions to counter macroeconomic and regulatory headwinds (such as the impact of GLP-1 drugs on certain device markets) and offensive acquisitions designed to secure high-growth, attractive therapeutic areas, including neurovascular, advanced diagnostics, and AI data platforms.

Key Investment Recommendations for H1/H2 2026

Deal prioritisation in 2026 must be temporally segmented based on regulatory milestones and proven financial return:

H1 2026 Focus (Regulatory & Compliance): Strategic MedTech buyers should prioritize targets that offer immediate compliance advantages. This emphasis is driven by the deadline for the FDA’s Quality Management System Regulation (QMSR) implementation in February 2026. Acquisitions providing modernised, digital Quality Management Systems (QMS) or expertise in integrating design controls and manufacturing documentation will be critical for securing compliance and market access.
H2 2026 Focus (Scalability & Outcome): Attention will shift toward HealthTech assets that deliver quantifiable financial efficiency. Prime targets will include providers specialising in AI-driven Revenue Cycle Management (RCM) and Provider Operations (Provider Ops), segments that currently capture the largest share of HealthTech funding.These sectors offer clear ROI potential, with AI projected to reduce annual U.S. healthcare costs by at least $150 Billion by 2026.

The fundamental market prediction is that the alleviation of antitrust risk, coupled with significant capital availability, empowers CEOs to execute acquisitions that secure platform-level technology (AI) and address deep-seated portfolio vulnerabilities, marking a definitive shift toward complex, necessary transformation.

Macroeconomic and Financial Foundations for Deal Acceleration

The foundation for accelerated HealthTech and MedTech M&A in 2026 rests upon a confluence of improved capital market conditions, unprecedented technological necessity, and the tactical deployment of private capital.

The Global M&A Resurgence and Capital Environment

Leading investment banks project a robust return to dealmaking. Goldman Sachs anticipates global M&A deal flow could rise to $3.9 Trillion in 2026, potentially surpassing the prior record set in 2021. This global acceleration is founded on resilient balance sheets and rising CEO confidence.

A primary enabler of this optimism is the anticipated stabilisation of financing conditions. M&A strength is explicitly linked to the expectation of lower interest rates. Favourable credit markets will encourage corporate entities to pursue acquisitions that had been previously deemed too expensive or financially risky during periods of high borrowing costs. In the U.S., total deal volume for transactions over $100 Million is projected to grow 3% in 2026, following a strong 9% rise in 2025, confirming sustained momentum.

Regionally, deal flow exhibits variation. While the Americas experienced declines in deal volume and value in the first half of 2025, market share was absorbed by Europe, the Middle East, and Asia (EMEA). European dealmakers remain cautiously optimistic, with 85% expecting to engage in M&A activity despite persistent challenges, including financing difficulties and valuation gaps. Emerging markets, such as India, are expected to demonstrate strong momentum specifically in health technologies.

The Influence of Private Equity (PE) Dry Powder

Private equity is forecasted to be a dominant force in 2026 dealmaking. PE deal volume is projected to increase by 5% in 2026, leveraging substantial dry powder positions that have accumulated during slower periods. A majority of healthcare respondents surveyed view high PE involvement as a primary driver for the market strengthening in 2026.

PE firms are strategically deploying capital, focusing on platform building and efficiency improvements through bolt-on acquisitions. A key tactic involves forming "club deals," where PE firms partner with corporate buyers to double down on specific, attractive therapeutic areas.This collaborative model allows for shared risk and deeper sector expertise.

Furthermore, PE funds, which have often deferred exits pending more favourable public market conditions, will increasingly utilise the strengthening M&A environment to divest assets. These exits are predominantly directed toward corporate buyers seeking data-rich, recurring-revenue assets. The readiness of PE to acquire mature, later-stage companies (Series B and beyond) also provides a crucial M&A-centric exit mechanism for VC-backed HealthTech and MedTech firms, circumventing the ongoing volatility of the IPO window.

The Global Cost-Control Mandate

Persistent margin pressures within sectors like MedTech continue to necessitate portfolio balancing and sell-side activity. This drive for efficiency is amplified by broader global economic trends. For the first time in three years, the global average medical trend rate is expected to drop back into single digits, forecasted at 9.8% in 2026.

Although a reduction in the medical trend rate is generally positive, it increases the pressure on Life Sciences and Health Care (LSHC) organisations to rigorously demonstrate cost-effectiveness in their operations. This dynamic ensures that M&A is heavily weighted toward acquisitions offering operational returns rather than purely innovative risk. Consequently, highly sought-after targets will include assets enabling supply chain optimisation, facility consolidation (such as Ambulatory Surgery Center acquisitions), and next-generation Revenue Cycle Management (RCM). These deals function as proactive countermeasures against persistent macroeconomic headwinds, directly aiming to shore up EBITDA margins.

2026 M&A Momentum Forecast: Key Drivers and Catalysts

Driver Category	2026 Outlook	Impact on Deal Value/Volume	Primary Rationale
Macroeconomic Climate	Optimistic, potential record-breaking global M&A volumes. Lower expected borrowing costs.	Strong increase in deal value (megadeals) and moderate volume growth. PE deployment accelerates.	Renewed CEO confidence; favorable credit conditions encouraging large acquisitions.
Regulatory (Antitrust)	Shift toward structural remedies and less stringent enforcement.	Enables large, transformative corporate M&A by reducing litigation risk.	Revocation of competition directives; increased willingness to accept divestitures.
Technological Integration	AI/GenAI moves from pilot projects to core infrastructure; buy-vs-build preference.	Significant valuation growth for tech-forward assets; AI is the key catalyst for megadeals.	AI drives efficiency and forms a quarter of megadeal rationale; incumbents prefer acquiring scalable solutions.
Investor Strategy (PE)	High dry powder; preference for scale and bolt-on acquisitions; exit environment improving.	Increased volume, especially in mid-market platform and club deals.	PE is positioned to close valuation gaps and provide M&A-centric exits for VCs.

The Regulatory Paradigm Shift: Enabling Mega-Deals

A key factor differentiating the 2026 forecast from prior years is the significant pivot in the U.S. regulatory environment concerning large-scale consolidation, coupled with critical deadlines for MedTech compliance.

The Great Antitrust Reversal and Deal Confidence

The incoming administration is expected to initiate a policy pivot by revoking prior competition executive orders, which broadly promoted aggressive antitrust enforcement. This shift signals a practical departure from the confrontational posture previously taken toward consolidation within the healthcare sector. The change is expected to manifest as a less-stringent regulatory environment, easing certain challenges for PE firms and enabling larger merger activity.

The critical change lies in the enforcement strategy of the Department of Justice (DOJ) and the Federal Trade Commission (FTC). Instead of pursuing outright litigation to block proposed deals, there is a greater willingness to resolve mergers through structural remedies, such as mandatory divestitures and conduct-based conditions. This drastically lowers the regulatory risk profile for strategic, large-scale HealthTech and MedTech mergers. The acceptance of structural remedies in major integrated healthcare mergers, exemplified by the UnitedHealth/Amedisys transaction, establishes a clear template for corporate development teams pursuing complex combinations in 2026.

While the enforcement posture is becoming more amenable to deal size, regulatory scrutiny remains intense in highly concentrated, niche markets. The blocked bid by GTCR BC Holdings to acquire Surmodics Inc. over concerns regarding market dominance in outsourced medical device coatings demonstrates that the focus is shifting to preserving competition within specific therapeutic or supply chains, rather than challenging overall transaction size.

MedTech Regulatory Harmonisation: The QMSR Mandate

The MedTech sector faces a crucial regulatory deadline: the FDA’s Quality Management System Regulation (QMSR) final rule, which harmonises US regulatory requirements with the international standard ISO 13485, is scheduled to take effect on February 2, 2026.

This mandate serves as an immediate, tactical M&A driver in the first half of 2026. Firms that proactively modernise their quality processes, update training, and invest in digital QMS platforms will gain a "strategic compliance advantage". Acquiring targets that have already achieved this transition ensures smoother international operations and eliminates the burden of a complex, costly internal overhaul.

Consequently, due diligence in MedTech M&A for 2026 will heavily scrutinise QMSR readiness, particularly the documentation compliance related to design controls and manufacturing processes. The costs and complexities associated with this global alignment effort mean that smaller, less financially robust device manufacturers may struggle to comply, driving smaller, strategic bolt-on acquisitions by larger incumbents seeking to integrate compliant, modernised operations.

Trade Policy and Supply Chain Vulnerability

A significant layer of uncertainty impacting MedTech M&A is the potential for trade restriction arising from the Section 232 investigation initiated by the U.S. Department of Commerce Bureau of Industry and Security (BIS). This investigation targets the effects of imports of medical equipment, devices, and consumables on national security. The investigation could conclude by May 2026 and potentially lead to the imposition of tariffs or import restrictions.

Should tariffs materialize, the cost of imported medical devices and components will rise immediately, threatening the already tight margins of many device manufacturers. This potential risk incentivises M&A focused on reshoring manufacturing capabilities and securing U.S.-based supply chain assets. Strategic buyers will look to acquire domestic production facilities to mitigate reliance on global supply chains that could become prohibitively expensive, particularly impacting MedTech consumables and device sectors.

MedTech M&A Focus Areas: Innovation, Efficiency and Portfolio Defence

MedTech M&A in 2026 will be characterised by aggressive moves to secure high-growth niches, integrate next-generation technology, and strategically manage portfolio risk, particularly in response to the GLP-1 drug phenomenon.

Strategic Imperatives for MedTech Incumbents

Ongoing margin pressures dictate that MedTech companies must continue portfolio balancing and leveraging divestitures to focus capital on high-growth therapeutic areas.Specific sectors showing notable investment activity include dental, nephrology, urology, and diagnostics.

A significant portion of deal rationale is driven by the necessity of a GLP-1 defensive strategy. The massive investment and adoption of metabolic and obesity-related drugs (eg. those involving GLP-1 analogs) pose a threat to device manufacturers reliant on co-morbidities (eg. specific orthopaedic or cardiovascular devices). Corporate buyers are engaging in offensive M&A to acquire assets in complementary or unaffected areas, such as neuro vascular devices, or defensive M&A to mitigate exposure to areas where demand might decrease.

Robotics and Minimally Invasive Surgery (MIS) Evolution

The sector encompassing surgical robotics, advanced imaging, and minimally invasive surgery platforms is set for accelerated M&A momentum in 2026. The prevailing trend is the democratisation of robotics, shifting adoption from high-volume academic centre's into community hospitals. This expansion is made possible by lower cost structures and greater accessibility, promising revolutionary advances in care delivery.

Deals in this space are fundamentally driven by the desire to integrate AI. The acquisition of Monogram Technologies by Zimmer Biomet, focused on its autonomous joint replacement platform, exemplifies the market’s focus on acquiring AI-driven, personalised orthopaedic surgery solutions. Strategic acquirers seek to buy surgical robotics data platforms and advanced diagnostics offerings that provide scalable, integrated systems, fulfilling the need for a capital-intensive "Big Exit" for VC-backed innovators.

High-Growth Device Sub-Sectors

Investor interest is heavily concentrated in therapeutic device areas that possess strong clinical demand fundamentals:

Neuro vascular and Cardiovascular: These segments are identified as high-growth areas. North America, with its established healthcare infrastructure and high prevalence of neurological conditions (such as stroke and cerebral aneurysms), continues to drive strong demand for advanced neurovascular devices, positioning companies in this sector as prime targets for acquisition.
Outpatient and Home-Based Care: Aligning with patient expectations for convenience and affordability, investors are intensely seeking devices and systems that enable complex procedures to be moved out of high-cost facilities and into Ambulatory Surgery Centers (ASCs) or the home setting. This trend reflects the industry’s response to the consumer mandate for accessible and affordable care options.
Bioelectronic Medicine: The European M&A outlook predicts continued expansion in "Electric Medicine." This category includes neurotechnology and bioelectronic devices, moving beyond traditional applications like deep-brain stimulation (DBS) to incorporate sophisticated Brain-Computer Interfaces (BCIs) and non-invasive neuromodulation technologies.

The growth of the wearable healthcare devices market, projected to reach $30 Billion in the U.S. by 2026, will stimulate M&A focused on targets that bridge the gap between consumer fitness tracking and clinical utility. Strategic buyers require that acquisitions, whether smartwatches or patches, possess "clinical teeth, meaning they must demonstrate clinical validation, real-time monitoring capabilities, EHR integration and a clear pathway for reimbursement (eg. Remote Patient Monitoring, RPM). M&A is being used to secure assets that promise measured clinical or financial outcomes, as buyers increasingly prioritise proven results over simple user engagement metrics.

HealthTech M&A Focus Areas: The AI Efficiency Mandate

HealthTech M&A in 2026 is fundamentally an infrastructure play, where AI and GenAI capabilities are acquired to automate and optimize the administrative and clinical workflows that account for a disproportionate amount of healthcare costs.

AI as the New HealthTech Infrastructure

Corporate acquirers overwhelmingly favour buying AI solutions rather than investing in protracted internal development. This "acquire, don't build" strategy minimises R&D time and quickly secures scalable tech platforms.

AI is the primary catalyst driving the increase in mega deals; approximately one quarter of transactions valued at $5 Billion or more have an AI theme. This surging interest has translated into rising valuations, particularly for seed and Series A companies focused on AI-driven solutions. GenAI is a critical M&A driver due to its demonstrated utility in automating tasks like clinical documentation, interaction transcription, and extracting key insights from medical text.

This focus on automation is necessary to close a critical organisational gap: despite high consumer adoption of GenAI for health reasons, only 15% of surveyed LSHC executives reported having adapted their governance to keep pace with the technology. This gap presents both a risk (algorithmic bias, data privacy) and an immense opportunity for acquiring organisations that can integrate compliant, scalable AI governance swiftly.

Provider Operations and Revenue Cycle Management (RCM) Consolidation

The consolidation in Provider Operations represents the most active sub-sector within HealthTech M&A, capturing 44% of healthtech investment dollars in 2024 and maintaining the highest deal volume.

This activity is strongly correlated with the financial reset occurring in RCM. Historically driven by offshore labor arbitrage, RCM is now migrating toward AI-first, U.S.-based architectures that introduce autonomy and efficiency. This shift is critical as health systems, payers, and PE firms seek to leverage AI's potential to reduce annual healthcare costs by $150 billion to $360 billion by 2026. Acquisitions targeting RCM, workflow automation, and analytics platforms are foundational for organisations seeking to optimise medical loss ratios (MLRs) and stabilise profitability against relentless cost compression.

Big Tech and Interoperability Acquisition Strategy

Big Tech entities, including Google, Amazon and Apple, are poised to drive strategic HealthTech M&A in 2026, catalysed by the government’s push for health data exchange. The Trump administration and CMS announced a sweeping initiative, supported by over 60 companies, for a digital health ecosystem based on the CMS Interoperability Framework, targeted for a 2026 rollout.

This framework mandates secure, real-time data exchange via FHIR APIs, replacing traditional methods.Big Tech M&A will focus on HealthTech companies that specialise in:

Interoperability platforms and data exchange infrastructure capable of seamless integration.
Patient-facing apps designed to manage chronic conditions (eg. obesity, diabetes) often utilising conversational AI and personalised support.
Software as a Medical Device (SaMD) that integrates clinical data and provides analytical value.

Big Tech’s entry is strategically aligned with consumer demand. Consumers prioritise convenience, access, and affordability, expecting experiences as simple as online banking. Since incumbent LSHC organisations often fail to prioritise these consumer-centric demands, Big Tech uses M&A as the fastest route to acquire trust and deliver the personalised, proactive care experience consumers are demanding.

Digital Therapeutics (DTx) and Value-Based Care Alignment

The Digital Therapeutics (DTx) market, expected to grow significantly, reaching nearly $5.0 Billion in 2025, is maturing. Its growth is intrinsically linked to the shift toward value-based care models. M&A in this space is highly selective, focusing only on assets that demonstrate clear financial and clinical outcomes.

Payer organisations are becoming increasingly sophisticated, often insisting on outcome-based contracts where full fees are contingent upon the solution reducing hospitalisations or improving quality scores.Consequently, investment strategies, particularly those of Venture Capital, are mandating that the viability of M&A targets be contingent on a clear, evidence-based plan for securing reimbursement viability, recognising that financial coverage is the true determinant of commercial success, superseding the necessity of mere FDA regulatory clearance.

Strategic Positioning and Deal Rationale in 2026

The M&A playbook for 2026 emphasises strategic depth and the urgency of pipeline renewal, driving a measurable shift in the type of deals executed.

Deal Type Shift: Transformative Acceleration

Analysis predicts that the US deal market will accelerate strategically in 2026, led by high-value, transformative transactions. While overall corporate deal volume is projected to increase by 3%, the deal value growth will be significantly higher due to an increased share of large and megadeals.

This acceleration in deal value reflects a change in corporate strategic rationale. CEOs are gaining confidence and moving to acquire transformative capabilities, specifically AI and next-generation technologies, to "rewire their businesses for resilience". Acquisitions are no longer primarily defensive, incremental bolt-ons; they are now necessary, large-scale platform acquisitions designed to achieve a rapid strategic objective, often aided by the increased predictability of the regulatory environment.

Corporate Buyer Playbook: Filling Pipeline Gaps

For large biopharma and MedTech companies, M&A remains the primary mechanism for pipeline renewal. The strategy is overwhelmingly to buy innovation rather than build it internally, particularly to quickly counter revenue losses resulting from looming patent cliffs. High-value targets are typically biotechs with late-stage assets, clean Intellectual Property (IP), and regulatory clarity.

The competitive pressure in the metabolic and obesity space, fuelled by GLP-1 drugs, has driven major multi-billion-dollar deals (eg. Pfizer/Metsera, Roche/89bio) that are expected to continue through 2026.These deals are defining the focus areas where capital is concentrated and signalling necessary portfolio shifts for MedTech and integrated health systems. Beyond therapeutics, strategic consolidation continues robustly in high-growth healthcare service areas, including home health, behavioural health, and dental.

Investor Exit Strategies and VC Deployment

The volatile IPO market and prolonged exit timelines dictate a refined strategy for Venture Capital (VC) deployment. Fund managers are enacting a "flight to quality," focusing capital on Series B and later rounds. This approach prioritises mature companies that have already addressed critical technical and initial clinical validation hurdles, minimising exposure to the early-stage, most capital-intensive phases of development.

For these mature assets, strategies must be explicitly structured to facilitate acquisition by large strategic corporates. Given the volatility of public market exits, M&A is recognised as the clearest pathway to achieving the necessary "Big Exit" required to offset the duration risk inherent in the sector.

A critical underlying factor driving strategic HealthTech M&A is the fundamental disconnect between consumer expectations and organisational priorities. Consumers aggressively prioritise convenience, access, and affordability, often moving faster than the LSHC organisations meant to serve them. For example, health systems could lose up to $54.5 billion over the next decade if they fail to offer virtual health options.Transformative M&A, specifically targeting AI-driven efficiency (RCM, automation) and personalised digital engagement platforms, is becoming the only scalable means for LSHC organisations to meet these cost-reduction expectations, maintain customer loyalty, and secure market share against well-funded, agile competitors.

Concluding Risk Assessment and Actionable Recommendations

Critical Investment Risks for 2026

Despite the bullish outlook for M&A, strategic buyers and investors must navigate several high-impact risks:

Policy Volatility and Supply Chain Exposure: While antitrust scrutiny is easing, the potential imposition of Section 232 tariffs on medical supplies by May 2026 poses a substantial and immediate threat to global supply chains, cost structures, and pricing stability in the MedTech sector.
AI Compliance and Data Risk: The rapid acquisition of GenAI capabilities introduces elevated due diligence requirements regarding algorithmic bias, data privacy, and intellectual property. Given the admitted failure of most LSHC executives to adapt governance for GenAI , firms that fail to implement robust integration plans focused on AI compliance expose themselves to significant post-acquisition regulatory penalties.
Consumer Trust and Affordability Deficit: Low consumer trust in biopharma (only 13% trust) and the documented gap between consumer demand for affordable, convenient care and the priorities of LSHC executives poses a long-term risk of market share erosion to competitors, especially Big Tech, which is rapidly acquiring consumer-centric digital solutions.

Recommendations for Strategic Buyers (MedTech/HealthTech Incumbents)

To maximise deal success and future-proof operations in 2026, incumbents should adopt the following strategies:

Prioritise Foundational AI and Compliance Acquisitions: Execute smaller, strategic bolt-on deals early in H1 2026 focused on RCM, Provider Ops, and QMS platforms to stabilise core operations and ensure MedTech regulatory compliance ahead of the February 2026 QMSR deadline.
Establish Clear Antitrust Contingency Planning: Leverage the favourable shift in antitrust posture by structuring large, transformative deals with pre-defined divestiture packages (structural remedies) to minimise regulatory review time and execution risk.
Double Down on Value-Based Alignment: Rigorously ensure that all technology acquisitions, particularly in Digital Therapeutics and diagnostics, possess validated clinical and financial outcomes to align future revenues with evolving, outcome-based reimbursement models and payer scrutiny.

Recommendations for Private Equity and Venture Capital

PE and VC strategies must be tailored to capitalise on the accelerated M&A environment and mitigate duration risk:

Target Late-Stage Quality: Concentrate capital deployment on Series B and later-stage companies that have demonstrated clinical traction and possess a clear, executable market access and reimbursement strategy, minimising exposure to early-stage development risk.
Utilise Club Deal Structures: Form club deals to manage the high capital requirements of expensive, high-growth platform acquisitions (eg. surgical robotics data platforms) with strategic corporate buyers. This guarantees a predetermined, favorable exit pathway and facilitates faster deployment of dry powder.
Implement Rigorous Technology and Compliance Diligence: Conduct deep technical diligence on the target’s AI capabilities, data governance, and regulatory readiness (especially QMSR and FHIR API alignment). A compliant, scalable, data-rich tech stack is the central driver of PE exit valuation in the 2026 market.

Predicted HealthTech and MedTech Acquisition Hotspots (2026)

Sector Sub-focus	Primary Acquisition Rationale	Key Buyer Profile	Strategic Significance
HealthTech: Provider Ops / RCM	Immediate operational efficiency gains; AI-driven cost reduction.	PE Firms, Large Health Systems, Integrated Payers.	Highest deal volume sub sector; RCM unit economics reset by AI; addresses margin compression.
MedTech: Surgical Robotics & Imaging	Expansion of MIS access; AI-driven personalisation and workflow improvement in ASC/community hospitals.	MedTech Incumbents (portfolio expansion and defense).	Accelerating democratisation; securing integrated AI-driven platforms (Monogram precedent).
HealthTech: Clinical DTx/SaMD	Acquiring clinically validated solutions tied to value-based care and clear reimbursement pathways.	Pharma/Biotech, Large Payers.	Shift from engagement to outcomes; necessity of securing reimbursement viability post-FDA clearance.
MedTech: Outpatient/ASC Systems	Shift of complex procedures from inpatient facilities to lower-cost ambulatory and home-based settings.	PE-backed Platforms, Strategic MedTech Incumbents.	Aligns M&A with consumer demands for affordability and accessibility.
HealthTech: Interoperability/Data Exchange	Securing access to real-time patient data; mandatory alignment with CMS FHIR API 2026 framework.	Big Tech (Amazon, Google, Apple), Large Integrated Health Systems.	Fast-track entry for Big Tech to earn consumer trust and provide proactive, personalised care.

Nelson Advisors > MedTech and HealthTech M&A

Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide #Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech